CDG Stock Overview A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Acorda Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Acorda Therapeutics Historical stock prices Current Share Price US$8.42 52 Week High US$21.80 52 Week Low US$5.64 Beta 1.43 1 Month Change 0% 3 Month Change -6.83% 1 Year Change 10.25% 3 Year Change -83.90% 5 Year Change -99.70% Change since IPO -98.76%
Recent News & Updates First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc. Aug 14
Acorda Therapeutics Files Form 15 Aug 13 Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million. Jul 12
Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc. Jul 04
Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024 Apr 27 Acorda Therapeutics Announces Delisting from Nasdaq Apr 17
See more updates First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc. Aug 14
Acorda Therapeutics Files Form 15 Aug 13 Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million. Jul 12
Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc. Jul 04
Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024 Apr 27 Acorda Therapeutics Announces Delisting from Nasdaq Apr 17
Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index Apr 12 Motion for Asset Sale Filed by Acorda Therapeutics, Inc. Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million. Apr 03
Motion for Joint Administration Filed by Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024 Mar 26
Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023 Nov 15
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA Nov 07
Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023 Aug 11
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Jun 27
Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market Jun 06
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing Jun 02
First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022) May 15
Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023 May 12
Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021) Mar 11
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement Feb 16
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A Hearing Dec 22
Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021) Nov 18
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021) Nov 03
Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027 Oct 28
Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 26
Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer Aug 20
Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021) Aug 06
Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022 Aug 06
Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock Market Jun 25
Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 May 17
First quarter 2022 earnings released: US$1.93 loss per share (vs US$3.53 loss in 1Q 2021) May 13
Insufficient new directors May 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 11
Acorda Therapeutics, Inc. Announces Board Changes Mar 07
Insufficient new directors Dec 06
Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020) Nov 11
Independent Director Barry Greene has left the company Aug 26
Independent Director Catherine D. Strader has left the company Aug 26
Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020) Aug 09
First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020) May 08
Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021 May 07
Revenue beats expectations Mar 05
Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019) Mar 05
Acorda Therapeutics Announces Executive Changes Feb 20
Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR). Feb 13
Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent Feb 12
Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic Index Jan 28
Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million. Jan 14
New 90-day high: €5.42 Jan 14
Third quarter 2020 earnings released: EPS US$0.15 Nov 05
Revenue beats expectations Nov 05
New 90-day high: €0.89 Nov 04
Acorda Therapeutics, Inc. to Report Q3, 2020 Results on Nov 03, 2020 Oct 28
Steven M. Rauscher to Resign as Member of Board of Directors of Acorda Therapeutics, Inc Oct 06
Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from S&P Global BMI Index Sep 21
New 90-day low - €0.40 Sep 08
New 90-day low - €0.50 Aug 19
First half earnings released Aug 06 Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Value Index Shareholder Returns CDG DE Biotechs DE Market 7D 0% 1.0% 1.9% 1Y 10.2% -4.3% 15.1%
See full shareholder returns
Return vs Market: CDG exceeded the German Market which returned 5.9% over the past year.
Price Volatility Is CDG's price volatile compared to industry and market? CDG volatility CDG Average Weekly Movement n/a Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CDG's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CDG's volatility change over the past year.
About the Company Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.
Show more Acorda Therapeutics, Inc. Fundamentals Summary How do Acorda Therapeutics's earnings and revenue compare to its market cap? CDG fundamental statistics Market cap €14.12m Earnings (TTM ) -€19.42m Revenue (TTM ) €108.53m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CDG income statement (TTM ) Revenue US$116.91m Cost of Revenue US$27.38m Gross Profit US$89.53m Other Expenses US$110.45m Earnings -US$20.92m
Last Reported Earnings
Jun 30, 2023
Earnings per share (EPS) -16.84 Gross Margin 76.58% Net Profit Margin -17.89% Debt/Equity Ratio 259.6%
How did CDG perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/09/02 03:06 End of Day Share Price 2023/06/05 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Acorda Therapeutics, Inc. is covered by 28 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Robert LeBoyer Aegis Capital Corporation Christopher Raymond Baird John Newman Canaccord Genuity
Show 25 more analysts 
